Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 2Uveal Melanoma 1Oligodendroglioma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Astrocytoma 1

Interventions

Ipilimumab 10pembrolizumab 7Nivolumab 7incomplete Freund's adjuvant 6Temozolomide 5Dacarbazine 5tebentafusp 4Sunitinib 4MART-1 Antigen 4Carboplatin 4CTLA-4 Antigen 4sargramostim 3montanide ISA 51 3aflibercept 3Paclitaxel 3Bevacizumab 3trametinib 2relatlimab 2olaparib 2lenvatinib 2cediranib 2Vorinostat 2Thalidomide 2Taxes 2Sorafenib 2Radiosurgery 2MAGEA3 protein, human 2Lenalidomide 2Interleukin-2 2Interleukin-12 Subunit p35 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uveal Melanoma × NSC 366140 × Clear all
NCT00003802 2012-12-17

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡